NO20021244L - Subunit-optimized fusion proteins - Google Patents

Subunit-optimized fusion proteins

Info

Publication number
NO20021244L
NO20021244L NO20021244A NO20021244A NO20021244L NO 20021244 L NO20021244 L NO 20021244L NO 20021244 A NO20021244 A NO 20021244A NO 20021244 A NO20021244 A NO 20021244A NO 20021244 L NO20021244 L NO 20021244L
Authority
NO
Norway
Prior art keywords
subunit
fusion proteins
optimized fusion
optimized
proteins
Prior art date
Application number
NO20021244A
Other languages
Norwegian (no)
Other versions
NO20021244D0 (en
Inventor
Dan Pollock
Harry M Meade
Klaus Bosslet
Original Assignee
Genzyme Transgenics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Transgenics Corp filed Critical Genzyme Transgenics Corp
Publication of NO20021244D0 publication Critical patent/NO20021244D0/en
Publication of NO20021244L publication Critical patent/NO20021244L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01031—Beta-glucuronidase (3.2.1.31)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
NO20021244A 1999-09-17 2002-03-13 Subunit-optimized fusion proteins NO20021244L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39907999A 1999-09-17 1999-09-17
PCT/US2000/025558 WO2001019842A1 (en) 1999-09-17 2000-09-18 Subunit optimized fusion proteins

Publications (2)

Publication Number Publication Date
NO20021244D0 NO20021244D0 (en) 2002-03-13
NO20021244L true NO20021244L (en) 2002-05-13

Family

ID=23578058

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021244A NO20021244L (en) 1999-09-17 2002-03-13 Subunit-optimized fusion proteins

Country Status (14)

Country Link
EP (1) EP1237900A4 (en)
JP (1) JP2003509038A (en)
KR (1) KR20020039346A (en)
CN (1) CN1379782A (en)
AU (1) AU781462B2 (en)
BR (1) BR0014524A (en)
CA (1) CA2384766A1 (en)
HU (1) HUP0202702A2 (en)
IL (1) IL148549A0 (en)
MX (1) MXPA02002768A (en)
NO (1) NO20021244L (en)
NZ (1) NZ517774A (en)
RU (1) RU2002110116A (en)
WO (1) WO2001019842A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
JP2005522192A (en) 2001-07-19 2005-07-28 パーラン セラピューティクス， インコーポレイテッド Multimeric proteins and methods of making and using multimeric proteins
CA2929846C (en) * 2013-11-19 2020-09-15 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized b-cell activating factor gene

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111748A0 (en) * 1993-12-03 1995-01-24 Zeneca Ltd Proteins
GB9406974D0 (en) * 1994-04-08 1994-06-01 Pharmaceutical Proteins Ltd Transgenic production
US5959171A (en) * 1994-08-17 1999-09-28 Pharming B.V. Method for the production of biologically active polypeptides in a mammal's
US5635363A (en) * 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
US6528699B1 (en) * 1997-02-25 2003-03-04 Genzyme Transgenics Corporation Transgenically produced non-secreted proteins
GB9708918D0 (en) * 1997-05-01 1997-06-25 Ppl Therapeutics Scotland Ltd Methods
ES2273497T3 (en) * 1998-06-15 2007-05-01 Gtc Biotherapeutics, Inc. FUSION PROTEIN OF THE SERIAL HUMAN ALBUMIN OF ERITROPOYETINA ANALOGA.

Also Published As

Publication number Publication date
NO20021244D0 (en) 2002-03-13
EP1237900A1 (en) 2002-09-11
KR20020039346A (en) 2002-05-25
RU2002110116A (en) 2004-03-10
BR0014524A (en) 2002-06-11
AU781462B2 (en) 2005-05-26
HUP0202702A2 (en) 2002-12-28
CN1379782A (en) 2002-11-13
NZ517774A (en) 2005-01-28
CA2384766A1 (en) 2001-03-22
IL148549A0 (en) 2002-09-12
WO2001019842A1 (en) 2001-03-22
MXPA02002768A (en) 2002-08-30
AU3883101A (en) 2001-04-17
JP2003509038A (en) 2003-03-11
EP1237900A4 (en) 2005-08-03
WO2001019842A9 (en) 2002-11-14

Similar Documents

Publication Publication Date Title
DK2236152T3 (en) Albumin Fusion Proteins
FR2800817B1 (en) HOMOCINETIC JOINT TRIPODE
IT1313881B1 (en) HOMOCINETIC JOINT
NO20016116D0 (en) Substituted heterocyclic fused gamma-carbolines
DE69832542D1 (en) fusion implant
NO982097L (en) peptides
IS6040A (en) Valdekoxib preparations
NO982098L (en) peptides
DE60038253D1 (en) connecting material
DE60004380D1 (en) JOINT ARRANGEMENT
ID29577A (en) PESTICIDE PROTEIN
GB9913437D0 (en) Fusion proteins
NO20021275D0 (en) Transgent produced fusion proteins
FR2791348B1 (en) POLYPEPTIDE Npt2B
NO20004167D0 (en) Caspase-8 interacting proteins
DE69925271D1 (en) ANGIOSTATIN-BINDING PROTEIN
NO20021244L (en) Subunit-optimized fusion proteins
DE10082298D2 (en) Chimeric proteins
FI991256A (en) Serving aid
DK0862197T3 (en) Fused Connection
NO20013933D0 (en) peptides
NO20012283D0 (en) Coupled peptides
NO20013699D0 (en) Me-4 protein
DE50009295D1 (en) NETWORK-FREE PREPARATIONS
ATE480262T1 (en) FUSION PROTEINS

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application